Concurrent radical cystectomy and extended lymph node dissection did not show benefit vs standard lymph node dissection in muscle invasive urothelial cancer.
Analysis of molecular subtypes of muscle-invasive bladder cancer can predict if a tumor is likely to respond to chemotherapy before surgery but is not associated with differences in survival.
Association of molecular subtypes in bladder cancer with response to neoadjuvant chemotherapy, progression and survival medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
An extended lymphadenectomy – removal of additional lymph nodes beyond the extent of the standard procedure – in patients undergoing radical cystectomy (removal of bladder and nearby tissues) because of clinically localized muscle-invasive bladder cancer provides no patient benefit as measured by disease-free survival or overall survival times.
An extended lymphadenectomy – removal of additional lymph nodes beyond the extent of the standard procedure – in patients undergoing radical cystectomy (removal of bladder and nearby tissues) because of clinically localized muscle-invasive bladder cancer provides no patient benefit as measured by disease-free survival or overall survival times. It does, however, increase the risk of adverse events (side effects) and post-surgical death. These primary results from the phase 3 SWOG S1011 clinical trial are being delivered in an oral presentation at the 2023 annual meeting of the American Society of Clinical Oncology in Chicago on June 5 (Abstract 4508).